Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome

Annals of the Rheumatic Diseases

Volumn 76, Issue 1, 2017, Pages 303-309

  Torene, Rebecca ^a   Nirmala, Nanguneri ^a   Obici, Laura ^b   Cattalini, Marco ^c   Tormey, Vincent ^d   Caorsi, Roberta ^e   Starck Schwertz, Sandrine ^f   Letzkus, Martin ^f   Hartmann, Nicole ^f   Abrams, Ken ^f   Lachmann, Helen ^g   Gattorno, Marco ^e  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY HOSPITAL GALWAY   (Ireland)

^e G GASLINI INSTITUTE   (Italy)

^f NOVARTIS PHARMA AG   (Switzerland)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; CYTOKINE; GRANULOCYTE ANTIBODY; I KAPPA B KINASE ALPHA; INTERLEUKIN 6; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CELL SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE TITRATION; GENE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IL 1B GENE; INFLAMMATION; INTRACELLULAR SIGNALING; MAPK14 GENE; MICROARRAY ANALYSIS; MONOCYTE; MULTICENTER STUDY; NEUTROPHIL COUNT; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; SINGLE DRUG DOSE; TNFRSF1A GENE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; LEUKOCYTE COUNT; MALE; METABOLISM; MIDDLE AGED; NEUTROPHIL; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CHILD; DRUG ADMINISTRATION SCHEDULE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-1BETA; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; RECEPTORS, TUMOR NECROSIS FACTOR; YOUNG ADULT;

EID: 84979666753     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209335     Document Type: Article

References (30)

1. Kimberley FC, Lobito AA, Siegel RM, et al. Falling into TRAPS - receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res Ther 2007; 9: 217.
2. Ter Haar N, Lachmann H, Özen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013; 72: 678-85.
3. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133-44.
4. Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002; 81: 349-68.
5. Vitale A, Rigante D, Lucherini OM, et al. Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediators Inflamm 2013; 2013: 939847.
6. Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis 2014; 73: 2160-7.
7. Gattorno M, Martini A. Beyond the NLRP3 inflammasome: autoinflammatory diseases reach adolescence. Arthritis Rheum 2013; 65: 1137-47.
8. Bachetti T, Chiesa S, Castagnola P, et al. Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis 2013; 72: 1044-52.
9. Dinarello CA Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-147.
10. Dinarello CA Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201: 1355-9.
11. Lobito AA, Kimberley FC, Muppidi JR, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006; 108: 1320-7.
12. Dickie LJ, Aziz AM, Savic S, et al. Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis 2012; 71: 2035-43.
13. Greco E, Aita A, Galozzi P, et al. The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-KB pathway. Arthritis Res Ther 2015; 17: 93.
14. Gattorno M, Pelagatti MA, Meini A, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58: 1516-20.
15. Obici L, Meini A, Cattalini M, et al. Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis 2011; 70: 1511-12.
16. Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206: 1029-36.
17. Dhimolea E. Canakinumab. mAbs 2010; 2: 3-13.
18. NCT01242813. An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 6-month follow-up in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS). https://clinicaltrials.gov/ct2/show/NCT01242813?term=NCT01242813&rank=1 (accessed 16 Aug 2015).
19. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396-406.
20. Negm OH, Mannsperger HA, McDermott EM, et al. A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS). Eur J Immunol 2014; 44: 2096-110.
21. Gattorno M, Obici L, Meini A, et al. Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome. Ann Rheum Dis 2012; 71(Suppl 3): 289.
22. Simon A, Park H, Maddipati R, et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci USA 2010; 107: 9801-6.
23. Dinarello CA, Ikejima T, Warner SJC, et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 1987; 139: 1902-10.
24. Kamata H, Honda S, Maeda S, et al. Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005; 120: 649-61.
25. Nedjai B, Hitman GA, Yousaf N, et al. Abnormal tumor necrosis factor receptor cell surface expression and NF-KB activation in tumor necrosis factor receptor-associated period syndrome. Arthritis Rheum 2008; 58: 273-83.
26. Churchman SM, Church LD, Savic S, et al. A novel TNFRSF1A splice mutation associated with increased nuclear factor kappaB (NF-KB) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 2008; 67: 1589-95.
27. D'Osualdo A, Ferlito F, Prigione I, et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis. Arthritis Rheum 2006; 54: 998-1008.
28. Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin Immunol 2009; 124: 1141-9.
29. Gattorno M, Tassi S, Carta S, et al. Pattern of interleukin-1 β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007; 56: 3138-48.
30. Bulua AC, Simon A, Maddipati R, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011; 208: 519-33.